Literature DB >> 35819739

The short-term effects of intranasal steroids on intraocular pressure in pediatric population.

Taylan Ozturk1, Ceren Durmaz Engin2, Seher Koksaldi3, Gul Arikan3.   

Abstract

PURPOSE: To evaluate the effect of intranasal mometasone furoate (INMF) on short-term intraocular pressure (IOP) alterations in children with allergic rhinitis (AR).
METHODS: Children diagnosed with AR and to whom INMF nasal spray had been firstly prescribed were enrolled. Cases with any ocular diseases except for refractive errors were excluded. Complete ophthalmologic examinations including IOP measurements using Tonopen XL were performed before the treatment as well as at the first and sixth weeks of follow-up. Demographics and ophthalmologic findings were noted and statistically analyzed.
RESULTS: Study population consisted of 62 right eyes of 62 children with a mean age of 8.55 ± 3.14 years. Of them, 29 were female (46.8%) and 33 were male (53.2%). Dilated fundoscopy revealed an enlarged Cup/Disc ratio in 12 eyes (19.4%). Family history of glaucoma was positive in 13 cases (21.0%). Mean best corrected visual acuity was found as 0.05 ± 0.08 logMAR. Initial IOP was 17.1 ± 2.3 mmHg; whereas it was measured as 18.2 ± 2.0 mmHg and 17.3 ± 2.1 mmHg at the first and sixth weeks of follow-up, respectively (p < 0.001). Both at the first and sixth weeks of follow-up, significant IOP rise was present in children with a positive family history of glaucoma (p < 0.001 and p = 0.003, respectively). Besides, increased IOP was found in participants with cupping revealed on fundoscopy at the first week of follow-up (p = 0.044).
CONCLUSION: Since children have greater risk for steroid-induced ocular hypertensive response than adults, ophthalmologic evaluation must be recommended in children receiving intranasal steroids.
© 2022. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Intranasal steroid; Intraocular pressure; Mometasone furoate; Pediatric glaucoma

Year:  2022        PMID: 35819739     DOI: 10.1007/s10792-022-02402-6

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.029


  22 in total

1.  Corticosteroids in the treatment of pediatric allergic rhinitis.

Authors:  G K Scadding
Journal:  J Allergy Clin Immunol       Date:  2001-07       Impact factor: 10.793

Review 2.  Steroid-induced iatrogenic glaucoma.

Authors:  M Reza Razeghinejad; L Jay Katz
Journal:  Ophthalmic Res       Date:  2011-07-13       Impact factor: 2.892

3.  Rising trend of allergic rhinitis prevalence among Turkish schoolchildren.

Authors:  Fatma Duksal; Ahmet Akcay; Tulay Becerir; Ahmet Ergin; Cem Becerir; Nermin Guler
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2013-07-02       Impact factor: 1.675

4.  Steroid-induced glaucoma and childhood blindness.

Authors:  Shikha Gupta; Pooja Shah; Sartaj Grewal; Abadh Kishore Chaurasia; Viney Gupta
Journal:  Br J Ophthalmol       Date:  2015-05-22       Impact factor: 4.638

5.  Inhaled steroid use and glaucoma.

Authors:  E B Dreyer
Journal:  N Engl J Med       Date:  1993-12-09       Impact factor: 91.245

6.  Acute effects of dexamethasone on intraocular pressure in glaucoma.

Authors:  R N Weinreb; J R Polansky; S G Kramer; J D Baxter
Journal:  Invest Ophthalmol Vis Sci       Date:  1985-02       Impact factor: 4.799

7.  Ocular-hypertensive response to topical steroids in children.

Authors:  A K Kwok; D S Lam; J S Ng; D S Fan; S J Chew; M O Tso
Journal:  Ophthalmology       Date:  1997-12       Impact factor: 12.079

Review 8.  Corticosteroid-induced glaucoma: a review of the literature.

Authors:  J P Kersey; D C Broadway
Journal:  Eye (Lond)       Date:  2006-04       Impact factor: 3.775

9.  Outcome of Ocular Steroid Hypertensive Response in Children.

Authors:  Savleen Kaur; Indu Dhiman; Sushmita Kaushik; Srishti Raj; Surinder S Pandav
Journal:  J Glaucoma       Date:  2016-04       Impact factor: 2.503

10.  Prostaglandin production by human trabecular cells: in vitro inhibition by dexamethasone.

Authors:  R N Weinreb; M D Mitchell; J R Polansky
Journal:  Invest Ophthalmol Vis Sci       Date:  1983-12       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.